Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)

Core Insights - Oncotelic Therapeutics, Inc. announced that three abstracts related to its investigational intravenous Deciparticle everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) [1][2] - Sapu003 is designed to address the limitations of oral mTOR inhibitors, such as poor bioavailability and dose-limiting toxicity, and is currently in a Phase 1 trial for hormone receptor-positive (HR⁺)/HER2⁻ metastatic breast cancer [2][3] - The studies highlight the clinical rationale, molecular biomarkers, and pharmacokinetic justification for Sapu003, showcasing the innovation of the Deciparticle nanomedicine platform [3][4] Company Overview - Oncotelic Therapeutics, Inc. was founded in 1988 and has undergone several name changes, with its current name adopted in November 2020 [4] - The company focuses on oncology drug development, particularly for rare pediatric cancers, and has received rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG) [4] - Oncotelic has also expanded its portfolio by acquiring PointR Data Inc. and AL-101 for the treatment of Parkinson's Disease and Erectile Dysfunction [5][6] Presentation Details - The presentations at SABCS will take place on December 11, 2025, and will cover topics such as predictive biomarkers and the rationale for the first-in-human trial of Sapu003 [3] - The studies were conducted in collaboration with Southern Oncology Clinical Research Unit (SOCRU), Ingenu CRO, and Medicilon, emphasizing a coordinated clinical-translational effort [3]